Putting Patients First: How the FDA Could Use Its Existing Powers to Reduce Post-Market Adverse Events

Indiana Health Law Review
doi 10.18060/18832
Full Text
Abstract

Available in full text

Date
Authors
Publisher

IUPUI University Library

Related search

Adverse Events Associated With Pediatric Use of Proton Pump Inhibitors: Analysis of the Fda Adverse Event Reporting System

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Association Between Myocarditis and Other Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Use: Analysis of the FDA Adverse Events Reporting System (FAERS)

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Serious Adverse Drug Events Reported to the Food and Drug Administration (FDA): Analysis of the FDA Adverse Event Reporting System (FAERS) 2006-2011 Database

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Adverse Events Releated to Antibiotic Use in Patients With Myasthenia Gravis

Open Forum Infectious Diseases
OncologyNeurology
2017English

Putting Patients' Interests First

Dental update
Dentistry
2013English

How Vouchers Could Change the Market for Education

Journal of Economic Perspectives
EconomicsEconometrics
2002English

Association of Adverse Events With Antibiotic Use in Hospitalized Patients

JAMA Internal Medicine
Internal Medicine
2017English

Large-Scale Mining Disease Comorbidity Relationships From Post-Market Drug Adverse Events Surveillance Data

BMC Bioinformatics
BiochemistryApplied MathematicsComputer Science ApplicationsStructural BiologyMolecular Biology
2018English

Alzheimer’s Disease and Intranasal Fluticasone Propionate in the FDA MedWatch Adverse Events Database

Journal of Alzheimer's Disease Reports
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy